LifeMD Announces Closing of $50 Million Revolving Credit Facility with Citizens Bank, N.A.
Rhea-AI Summary
LifeMD (Nasdaq: LFMD) closed a new senior secured revolving credit facility with Citizens Bank providing up to $50 million of total availability, consisting of $30 million committed availability plus an accordion option of up to $20 million. The facility matures on January 2, 2029. As of closing, no amount was drawn and the company stated it expects existing cash and cash flow to fund organic growth. Interest is priced on a leverage-linked grid at either Term SOFR +150–225 bps or Alternate Base Rate +50–125 bps, with unused-commitment fees of 0.225%–0.30% and no upfront fee.
Positive
- $50M total availability including $30M committed
- Facility includes $20M accordion option
- No draws at close; preserves existing cash balances
- No upfront fee reduces initial financing cost
Negative
- Interest spread up to 225 bps increases borrowing cost if drawn
- Unused-commitment fees of up to 0.30% create ongoing costs
- Pricing tied to leverage could raise rates if leverage increases
- Maturity on Jan 2, 2029 creates future refinancing risk
News Market Reaction 11 Alerts
On the day this news was published, LFMD gained 7.93%, reflecting a notable positive market reaction. Argus tracked a peak move of +2.7% during that session. Our momentum scanner triggered 11 alerts that day, indicating notable trading interest and price volatility. This price movement added approximately $15M to the company's valuation, bringing the market cap to $205M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
LFMD was up 12.03% pre-news, while peers showed mixed, smaller moves (e.g., SLP +5.15%, SOPH -2.13%), indicating a stock-specific move rather than a broad sector rotation.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Dec 26 | Preferred dividend | Neutral | -12.5% | Declared cash dividend on 8.875% Series A preferred shares. |
| Nov 24 | Awards/recognition | Positive | +3.1% | Recognition by Deloitte Fast 500 and TIME for revenue growth. |
| Nov 17 | Earnings results | Positive | +2.2% | Q3 2025 revenue and EBITDA growth with debt reduction and cash build. |
| Nov 17 | Commercial partnership | Positive | +2.2% | Expanded GLP-1 collaboration with Novo Nordisk and new pricing offer. |
| Nov 10 | Conference participation | Neutral | -2.1% | BTIG Digital Health Forum participation and panel appearance. |
LFMD has tended to rise on clearly positive fundamentals and recognition news, while more neutral announcements (dividend, conference participation) have sometimes seen negative next-day moves.
Over the last several months, LifeMD reported stronger Q3 2025 results with revenue of $60.2M and improved profitability, divested most of WorkSimpli at an enterprise value of $65.0M, and highlighted growth in virtual care and GLP-1 offerings. Recognition from Deloitte and TIME underscored revenue growth and financial stability. A preferred dividend and conference participation had mixed share reactions. The new revolving credit facility adds another balance-sheet tool alongside prior debt repayment and cash generation.
Market Pulse Summary
The stock moved +7.9% in the session following this news. A strong positive reaction aligns with the addition of a $50 million senior secured revolving credit facility that closed with a $0 drawn balance, enhancing flexibility without immediate leverage. This came as LFMD traded far below its $15.84 52-week high and under its $7.39 200-day MA, with volume running at 2.02x its 20-day average. Investors may weigh this new capacity against recent insider net selling and prior accounting adjustments.
Key Terms
revolving credit facility financial
senior secured financial
accordion option financial
term sofr financial
basis points financial
AI-generated analysis. Not financial advice.
NEW YORK, Jan. 06, 2026 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care and pharmacy services, today announced the closing of a new senior secured revolving credit facility (“RCF”) with Citizens Bank, N.A. (“Citizens”). The facility has a maturity date of January 2, 2029 and provides for up to
“We are very pleased to close this revolving credit facility with Citizens, a leading national bank. The availability of the additional capital is competitively priced with no upfront fee and provides significant financial flexibility to support potential corporate development and/or shareholder value creation initiatives. We appreciate the support and confidence of Citizens in providing this facility and believe the RCF further underscores the strength and outlook of our business,” said Marc Benathen, Chief Financial Officer of LifeMD.
Based on a pricing grid tied to Company leverage, loans under the facility bear interest based on either (x) Term SOFR plus an applicable spread ranging between 150 basis points and 225 basis points or (y) the Alternate Base Rate plus an applicable spread ranging between 50 basis points and 125 basis points. Fees assessed on the committed unused portion of the facility range from
About LifeMD, Inc.
LifeMD® is a leading provider of virtual primary care. LifeMD offers telemedicine, access to laboratory and pharmacy services, and specialized treatment across more than 200 conditions, including primary care, men’s and women's health, weight management, and hormone therapy. The Company leverages a vertically integrated, proprietary digital care platform, a 50-state affiliated medical group, a state-of-the-art affiliated compounding pharmacy, and a U.S.-based patient care center to increase access to high-quality and affordable care. For more information, please visit LifeMD.com.
Cautionary Note Regarding Forward Looking Statements
This news release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended; Section 21E of the Securities Exchange Act of 1934, as amended; and the safe harbor provision of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this news release may be identified by the use of words such as: “believe,” “expect,” “anticipate,” “project,” “should,” “plan,” “will,” “may,” “intend,” “estimate,” predict,” “continue,” and “potential,” or, in each case, their negative or other variations or comparable terminology referencing future periods. Examples of forward-looking statements include, but are not limited to, statements regarding our financial outlook and guidance, short and long-term business performance and operations, future revenues and earnings, regulatory developments, legal events or outcomes, ability to comply with complex and evolving regulations, market conditions and trends, new or expanded products and offerings, growth strategies, underlying assumptions, and the effects of any of the foregoing on our future results of operations or financial condition.
Forward-looking statements are not historical facts and are not assurances of future performance. Rather, these statements are based on our current expectations, beliefs, and assumptions regarding future plans and strategies, projections, anticipated and unanticipated events and trends, the economy, and other future conditions, including the impact of any of the aforementioned on our future business. As forward-looking statements relate to the future, they are subject to inherent risk, uncertainties, and changes in circumstances and assumptions that are difficult to predict, including some of which are out of our control. Consequently, our actual results, performance, and financial condition may differ materially from those indicated in the forward-looking statements. These risks and uncertainties include, but are not limited to, “Risk Factors” identified in our filings with the Securities and Exchange Commission, including, but not limited to, our most recently filed Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and any amendments thereto. Even if our actual results, performance, or financial condition are consistent with forward-looking statements contained in such filings, they may not be indicative of our actual results, performance, or financial condition in subsequent periods.
Any forward-looking statement made in the news release is based on information currently available to us as of the date on which this release is made. We undertake no obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise, except as may be required under applicable law or regulation.
Investor Contact
Marc Benathen, Chief Financial Officer
marc@lifemd.com
Media Contact
Jessica Friedeman, Chief Marketing and Product Officer
press@lifemd.com